Clinical Trial

A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label, multicenter, dose-escalation, dose-expansion and efficacy-expansion phase I clinical study to evaluate the tolerability, safety, pharmacokinetics and preliminary antitumor activity of QLS2309 injection in patients with CD70+ relapsed/refractory hematologic malignancies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-07.
Status change: Not Yet Recruiting → Recruiting 2025-12-29
Trial Details
NCT Number NCT07173595
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Relapsed or Refractory Hematologic Malignancies
Enrollment 186 participants
Start Date 2025-12-05
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-02